AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 42 min read$SYRE

Burrows Scott L sold $184K of SYRE

Burrows Scott L (Chief Financial Officer) sold 2,599 shares of Spyre Therapeutics, Inc. (SYRE) at $70.77 ($0.18M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Burrows Scott L
Published Jun 4, 2026, 1:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SYRE
Neutral
medium confidence
Mentioned
$SYRE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYRENeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new company-specific fundamentals (no earnings, trial, deal, or regulatory action mentioned).

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 structure generally limits immediate trading signal strength.

03

What to watch

The filing does not disclose reasons for sale; traders should avoid over-interpreting 10b5-1 transactions as bearish fundamentals.

Relevance 6/10Novelty 3/10Timing: Filed June 3; sale executed June 1 (10b5-1 open-market).

Background

This is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics (SYRE).

Company-level read

Ticker impact

$SYRENeutralMedium confidence
Context

Spyre Therapeutics CFO Burrows Scott L sold $183,931 of SYRE shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Near-term impact likely muted; any reaction may be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 plan, which typically reduces interpretive weight versus unscheduled selling.

Market effects

Sector

Minimal—single-company insider transaction with no stated operational/regulatory catalyst.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Because the sale is pre-arranged, it could be mechanically timed around liquidity needs without reflecting negative outlook.

Key entities

  • issuer
    Spyre Therapeutics, Inc.

    SYRE, subject of the Form 4 insider sale by its CFO.

  • insider
    Burrows Scott L

    CFO who sold 2,599 SYRE shares at $70.7700 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SYRE insider trading history →

Related articles

SEP 17
$SYREMedAI 9/10

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

Spyre Therapeutics (SYRE) reported that its anti-IL-23 antibody, SPY003, met primary endpoints in a Phase 2 trial, showing a 10.0-point reduction in Robart’s Histopathology Index score. This follows successful results for SPY001 and SPY002, completing proof-of-concept for all three molecules in its IBD portfolio. The company has $1.1 billion in cash, enough to fund operations into 2029. Part B of the SKYLINE trial, testing drug combinations, is still enrolling, with data expected in 2027. Spyre

insidermonkey.com2 min
SEP 11
$SYREMedAI 8/10

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

Spyre Therapeutics (SYRE) reported Phase 2 trial results for SPY003 in ulcerative colitis patients, showing a 10-point decline in tissue inflammation and 20% clinical remission. The study lacked a control arm, and further testing is needed. The company has $1.15B in cash and expects funding into 2029. Part B of the trial is enrolling, with results expected in 2027.

insidermonkey.com2 min
AUG 27
$SYREMedAI 8/10

Top Biotechnology Stock Pick from Guggenheim

Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.

investing.com2 min
AUG 26
$SYREHighAI 8/10

Why is Spyre Therapeutics stock sliding today?

Spyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.

investing.com2 min